analysts, page-22

I think that Kakala is essentially right in seeing MSB as a $6 stock for the time being. I think the market has determined that nothing short of full FDA approval of CHF will shift the sp and that is going to be 2 or 3 years off and may never happen (even the positive analysts at Bell Potter estimate there's a 40% chance it will fail). Having said that, if it succeeds (60% chance) that's got to see a trippling of the sp. I don't think the upcoming Diabetes trial results will make any difference to the sp either.

I spent this week looking at what other stem cell companies are doing and a lot of them are reporting successes in the same indications at phase 1/2 level and their market capitalisation are a fraction of MSB so we can't expect positive Phase 2 announcements to shift the sp.